Sumatriptan (transdermal)

Jump to: navigation, search
Sumatriptan (transdermal)
Adult Indications & Dosage
Pediatric Indications & Dosage
Contraindications
Warnings & Precautions
Adverse Reactions
Drug Interactions
Use in Specific Populations
Administration & Monitoring
Overdosage
Pharmacology
Clinical Studies
How Supplied
Images
Patient Counseling Information
Precautions with Alcohol
Brand Names
Look-Alike Names

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Turky Alkathery, M.D. [2]

Disclaimer

WikiDoc MAKES NO GUARANTEE OF VALIDITY. WikiDoc is not a professional health care provider, nor is it a suitable replacement for a licensed healthcare provider. WikiDoc is intended to be an educational tool, not a tool for any form of healthcare delivery. The educational content on WikiDoc drug pages is based upon the FDA package insert, National Library of Medicine content and practice guidelines / consensus statements. WikiDoc does not promote the administration of any medication or device that is not consistent with its labeling. Please read our full disclaimer here.

Overview

Sumatriptan (transdermal) is a serotonin (5HT) 1b/1d receptor agonist that is FDA approved for the treatment of migraine with or without aura in adults. Common adverse reactions include application site pain, paresthesia, pruritus, warmth, and discomfort.

Adult Indications and Dosage

FDA-Labeled Indications and Dosage (Adult)

Indications

  • Sumatriptan (transdermal) is indicated for the acute treatment of migraine with or without aura in adults.
  • Limitations of Use:
  • Use only if a clear diagnosis of migraine has been established.
  • If a patient has no response to the first migraine attack treated with sumatriptan (transdermal) reconsider the diagnosis of migraine before sumatriptan (transdermal) is administered to treat any subsequent attacks.
  • Sumatriptan (transdermal) is not intended for the prevention of migraine attacks.

Dosage

  • Sumatriptan (transdermal) is for transdermal use only and is designed for patient self-administration to the upper arm or thigh (see Figure 1). Sumatriptan (transdermal) should not be applied to other areas of the body. Sumatriptan (transdermal) should not be cut.
  • The maximum recommended single dose is one sumatriptan (transdermal) iontophoretic transdermal system (TDS). No more than two sumatriptan (transdermal) TDS should be used in any 24 hour period, and the second sumatriptan (transdermal) TDS should be applied no sooner than 2 hours after activation of the first sumatriptan (transdermal) TDS. There is no evidence of benefit for the use of a second sumatriptan (transdermal) TDS to treat headache recurrence or incomplete headache relief during a migraine attack.
  • Sumatriptan (transdermal) should be applied to dry intact, non-irritated skin on the upper arm or thigh on a site that is relatively hair free and is without scars, tattoos, abrasions, or other skin conditions (i.e., generalized skin irritation or disease including eczema, psoriasis, melanoma, contact dermatitis). Sumatriptan (transdermal) should not be applied to a previous application site until the site remains erythema free for at least 3 days.
This image is provided by the National Library of Medicine.
  • Sumatriptan (transdermal) delivers 6.5 mg of sumatriptan over 4 hours. Once applied, the activation button must be pushed, and the red light emitting diode (LED) will turn on. sumatriptan (transdermal) TDS must be applied and activated within 15 minutes of initiation of assembly. When dosing is completed, the system stops operating and the activation light turns off, signaling that the system can be removed. Once dosing is completed, the system cannot be reactivated. If the light turns off before 4 hours, dosing has stopped and sumatriptan (transdermal) can be removed. If headache relief is incomplete, a second sumatriptan (transdermal) TDS can be applied to a different site.
  • The sumatriptan (transdermal) TDS should remain in place for 4 hours or until the red LED light goes off. The iontophoretic device can be secured with medical tape if needed.
  • The safety of using more than 4 sumatriptan (transdermal) in one month has not been established.
  • Sumatriptan (transdermal) is for single use only. After use, the TDS should be folded so the adhesive side sticks to itself and safely discarded away from children and pets. Sumatriptan (transdermal) contains lithium-manganese dioxide batteries; it should be disposed in accordance with state and local regulations.

Off-Label Use and Dosage (Adult)

Guideline-Supported Use

  • There is limited information regarding Off-Label Guideline-Supported Use of Sumatriptan (transdermal) in adult patients.

Non–Guideline-Supported Use

  • There is limited information regarding Off-Label Non–Guideline-Supported Use of Sumatriptan (transdermal) in adult patients.

Pediatric Indications and Dosage

FDA-Labeled Indications and Dosage (Pediatric)

  • Safety and effectiveness in pediatric patients have not been established.

Off-Label Use and Dosage (Pediatric)

Guideline-Supported Use

  • There is limited information regarding Off-Label Guideline-Supported Use of Sumatriptan (transdermal) in pediatric patients.

Non–Guideline-Supported Use

  • There is limited information regarding Off-Label Non–Guideline-Supported Use of Sumatriptan (transdermal) in pediatric patients.

Contraindications

  • Sumatriptan (transdermal) is contraindicated in patients with:

Warnings

Risk of Injury During Magnetic Resonance Imaging (MRI) Procedure

  • Sumatriptan (transdermal) contains metal parts and must be removed before an MRI procedure.

Allergic Contact Dermatitis

  • Use of sumatriptan (transdermal) may lead to allergic contact dermatitis (ACD). In two long-term open-label studies where patients were allowed to treat multiple migraine attacks for up to 1 year, the overall adverse event rate of ACD was 4%. sumatriptan (transdermal) should be discontinued if ACD is suspected. Erythema is commonly seen with use of sumatriptan (transdermal) and is not by itself an indication of sensitization. Following sensitization with sumatriptan (transdermal), erythematous plaque and/or erythemato-vesicular or erythemato-bullous eruptions may develop. Clinical course is characterized by crescendo phenomenon of worsening pruritus and appearance over time with slower resolution to normal of affected skin areas.
  • Patients sensitized from use of sumatriptan (transdermal), as evidenced by development of ACD, may develop systemic sensitization or other systemic reactions if sumatriptan-containing products are taken via other routes, e.g., orally or subcutaneously. It is possible that some patients who developed ACD with sumatriptan by exposure to sumatriptan (transdermal), and who have developed systemic sensitization, may not be able to take sumatriptan in any form.
  • Patients who develop ACD with sumatriptan (transdermal) and require treatment with sumatriptan via other routes should receive their first subsequent dose under close medical supervision.

Myocardial Ischemia, Myocardial Infarction, and Prinzmetal’s Angina

  • The use of sumatriptan (transdermal) is contraindicated in patients with ischemic or vasospastic CAD. There have been rare reports of serious cardiac adverse reactions, including acute myocardial infarction, occurring within a few hours following administration of sumatriptan. Some of these reactions occurred in patients without known CAD. 5-HT1 agonists, including sumatriptan (transdermal), may cause coronary artery vasospasm (Prinzmetal’s angina), even in patients without a history of CAD.
  • Perform a cardiovascular evaluation in triptan-naive patients who have multiple cardiovascular risk factors (e.g., increased age, diabetes, hypertension, smoking, obesity, strong family history of CAD) prior to using sumatriptan (transdermal). Do not use sumatriptan (transdermal) if there is evidence of CAD or coronary artery vasospasm. For patients with multiple cardiovascular risk factors who have a negative cardiovascular evaluation, consider using the first sumatriptan (transdermal) TDS in a medically supervised setting and performing an electrocardiogram (ECG) upon activation of sumatriptan (transdermal). For such patients, consider periodic cardiovascular evaluation in intermittent long-term users of sumatriptan (transdermal).

Arrhythmias

  • Life-threatening disturbances of cardiac rhythm, including ventricular tachycardia and ventricular fibrillation leading to death, have been reported within a few hours following the administration of 5-HT1 agonists. Discontinue sumatriptan (transdermal) if these disturbances occur. Sumatriptan (transdermal) is contraindicated in patients with Wolff-Parkinson-White syndrome or arrhythmias associated with other cardiac accessory conduction pathway disorders.

Chest, Throat, Neck and/or Jaw Pain/Tightness/Pressure

  • Sensations of tightness, pain, pressure, and heaviness in the chest, throat, neck, and jaw commonly occur after treatment with sumatriptan and are usually non-cardiac in origin. However, perform a cardiac evaluation if these patients are at high cardiac risk. The use of sumatriptan (transdermal) is contraindicated in patients shown with CAD and those with Prinzmetal’s variant angina.

Cerebrovascular Events

  • Cerebral hemorrhage, subarachnoid hemorrhage, and stroke have occurred in patients treated with 5-HT1 agonists, and some have resulted in fatalities. In a number of cases, it appears possible that the cerebrovascular events were primary, the 5-HT1 agonist having been administered in the incorrect belief that the symptoms experienced were a consequence of migraine when they were not.
  • As with other acute migraine therapies, before treating headaches in patients not previously diagnosed as migraineurs, and in migraineurs who present with atypical symptoms, exclude other potentially serious neurological conditions. Sumatriptan (transdermal) is contraindicated in patients with a history of stroke or TIA.

Other Vasospasm Reactions

  • 5-HT1 agonists, including sumatriptan (transdermal), may cause non-coronary vasospastic reactions, such as peripheral vascular ischemia, gastrointestinal vascular ischemia and infarction (presenting with abdominal pain and bloody diarrhea), splenic infarction, and Raynaud’s syndrome. In patients who experience symptoms or signs suggestive of a vasospastic reaction following the use of any 5-HT1 agonist, rule out a vasospastic reaction before using sumatriptan (transdermal).
  • Reports of transient and permanent blindness and significant partial vision loss have been reported with the use of 5-HT1 agonists. Since visual disorders may be part of a migraine attack, a causal relationship between these events and the use of 5-HT1 agonists have not been clearly established.

Medication Overuse Headache

  • Overuse of acute migraine drugs (e.g., ergotamine, triptans, opioids, combination of drugs for 10 or more days per month) may lead to exacerbation of headache (medication overuse headache). Medication overuse headache may present as migraine-like daily headaches or as a marked increase in frequency of migraine attacks. Detoxification of patients, including withdrawal of the overused drugs, and treatment of withdrawal symptoms (which often includes a transient worsening of headache) may be necessary.

Serotonin Syndrome

  • Serotonin syndrome may occur with triptans, including sumatriptan (transdermal), particularly during coadministration with selective serotonin reuptake inhibitors (SSRIs), serotonin norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), and MAO inhibitors. Serotonin syndrome symptoms may include mental status changes (e.g., agitation, hallucinations, coma), autonomic instability (e.g., tachycardia, labile blood pressure, hyperthermia), neuromuscular aberrations (e.g., hyperreflexia, incoordination), and/or gastrointestinal symptoms (e.g., nausea, vomiting, diarrhea). The onset of symptoms usually occurs within minutes to hours of receiving a new or a greater dose of a serotonergic medication. Discontinue sumatriptan (transdermal) if serotonin syndrome is suspected.

Increase in Blood Pressure

  • Significant elevation in blood pressure, including hypertensive crisis with acute impairment of organ systems, has been reported on rare occasions in patients treated with 5-HT1 agonists, including patients without a history of hypertension. Monitor blood pressure in patients treated with sumatriptan (transdermal). Sumatriptan (transdermal) is contraindicated in patients with uncontrolled hypertension.

Anaphylactic/Anaphylactoid Reactions

  • Anaphylactic/anaphylactoid reactions have occurred in patients receiving sumatriptan. Such reactions can be life threatening or fatal. In general, anaphylactic reactions to drugs are more likely to occur in individuals with a history of sensitivity to multiple allergens. Sumatriptan (transdermal) is contraindicated in patients with prior serious anaphylactic reaction.

Seizures

  • Seizures have been reported following administration of sumatriptan. Some have occurred in patients with either a history of seizures or concurrent conditions predisposing to seizures. There are also reports in patients where no such predisposing factors are apparent. sumatriptan (transdermal) should be used with caution in patients with a history of epilepsy or conditions associated with a lowered seizure threshold.

Electrically-active Implantable or Body-worn Medical Devices

  • Sumatriptan (transdermal) should not be applied in areas near or over electrically-active implantable or body-worn medical devices (e.g., implantable cardiac pacemaker, body-worn insulin pump, implantable deep brain stimulator).

Adverse Reactions

Clinical Trials Experience

  • Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared with rates in the clinical trials of another drug and may not reflect the rates observed in practice.
  • In two long-term, open-label studies in which patients were allowed to treat multiple migraine attacks for up to 1 year, 15% (99 out of 662) withdrew from the study because of adverse reaction. The most common adverse reactions leading to withdrawal from the study were contact dermatitis (4%) and application site pain (4%).
  • The most common adverse reactions (≥ 5%) in a controlled single dose study were application site pain, paresthesia, pruritus, warmth, and discomfort.

Controlled single dose acute migraine study

  • Table 1 lists adverse reactions that occurred at a frequency of 2% or greater in a controlled clinical study of sumatriptan (transdermal) in patients with acute migraine (Study 1). In that study, patients randomized to the control group used the same activated iontophoretic transdermal delivery system (TDS) as patients randomized to sumatriptan (transdermal), with the only difference being the absence of sumatriptan in the drug reservoir. Therefore, patients in the control group were exposed to same TDS-related risks as patients in the sumatriptan (transdermal) group, minus the risks related to sumatriptan. Only reactions that occurred at a frequency of 2% or more in patients treated with sumatriptan (transdermal) or control are included in Table 1.
This image is provided by the National Library of Medicine.
  • The incidence of "atypical sensations" adverse events (paresthesia, sensation warm/cold) and "pain and other pressure sensations" (chest pain/tightness/pressure/heaviness or neck/throat/jaw pain, tightness, pressure or heaviness) was 2% each in sumatriptan (transdermal)-treated patients, vs. 0% in the control group. Application site bruising was reported in 2 sumatriptan (transdermal)-treated patients (0.9%) vs. no patient in the control group.
  • Subgroup analyses of age (≤41 years, >41 years), race (Caucasian, non-Caucasian) and body mass index (BMI) (≤25.7 mg/kg2, >25.7 mg/kg2) showed no difference between subgroups for adverse events.

Skin Irritation Examination

  • In Study 1, patients performed their own examination of the TDS application site at 4, 12, and 24 hours post TDS activation, and daily thereafter until resolution. Skin irritation examination scores are summarized in Table 2. The median time to "no redness" was 2.6 days for sumatriptan (transdermal) compared with 0.3 day in the control group.
This image is provided by the National Library of Medicine.

Application site reactions across clinical studies (Controlled single dose acute migraine study and long term safety studies)

  • In the controlled and uncontrolled clinical studies combined (n = 796 unique sumatriptan (transdermal)-treated subjects), the frequency of application site reactions of clinical interest is presented in Table 3.
This image is provided by the National Library of Medicine.

Postmarketing Experience

There is limited information regarding Sumatriptan (transdermal) Postmarketing Experience in the drug label.

Drug Interactions

Ergot-Containing Drugs

  • Ergot-containing drugs have been reported to cause prolonged vasospastic reactions. Because these effects may be additive, use of ergotamine-containing or ergot-type medications (like dihydroergotamine or methysergide) and sumatriptan (transdermal) within 24 hours of each other is contraindicated.

Monoamine Oxidase-A Inhibitors

  • MAO-A inhibitors increase systemic exposure by 2-fold. Therefore, the use of sumatriptan (transdermal) in patients receiving MAO-A inhibitors is contraindicated.

Other 5-HT1 Agonists

  • Because their vasospastic effects may be additive, coadministration of sumatriptan (transdermal) and other 5-HT1 agonists (e.g., triptans) within 24 hours of each other is contraindicated.

Selective Serotonin Reuptake Inhibitors/Serotonin Norepinephrine Reuptake Inhibitors and Serotonin Syndrome

  • Cases of serotonin syndrome have been reported during coadministration of triptans and SSRIs or SNRIs, SNRIs, TCAs, and MAO inhibitors.

Use in Specific Populations

Pregnancy

Pregnancy Category (FDA): C

  • There are no adequate and well-controlled studies in pregnant women. sumatriptan (transdermal) should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.
  • When sumatriptan was administered intravenously to pregnant rabbits daily throughout the period of organogenesis, embryolethality was observed at doses at or close to those producing maternal toxicity. Oral administration of sumatriptan to rabbits during organogenesis was associated with increased incidences of fetal vascular and skeletal abnormalities; the highest no-effect dose for these effects was 15 mg/kg/day. The intravenous administration of sumatriptan to pregnant rats throughout organogenesis did not produce evidence of embryolethality. The subcutaneous administration of sumatriptan to pregnant rats prior to and throughout pregnancy did not produce evidence of embryolethality or teratogenicity.


Pregnancy Category (AUS): There is no Australian Drug Evaluation Committee (ADEC) guidance on usage of Sumatriptan (transdermal) in women who are pregnant.

Labor and Delivery

There is no FDA guidance on use of Sumatriptan (transdermal) during labor and delivery.

Nursing Mothers

  • It is not known whether sumatriptan is excreted in human milk following transdermal administration. Because many drugs are excreted in human milk, and because of the potential for serious adverse reactions in nursing infants from sumatriptan (transdermal), a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother.

Pediatric Use

  • Safety and effectiveness in pediatric patients have not been established.
  • Two controlled clinical trials evaluated sumatriptan nasal spray (5 to 20 mg) in 1,248 adolescent migraineurs aged 12 to 17 years who treated a single attack. The trials did not establish the efficacy of sumatriptan nasal spray compared with placebo in the treatment of migraine in adolescents. Adverse reactions observed in these clinical trials were similar in nature to those reported in clinical trials in adults.
  • Five controlled clinical trials (2 single-attack studies, 3 multiple-attack studies) evaluating oral sumatriptan (25 to 100 mg) in pediatric patients aged 12 to 17 years enrolled a total of 701 adolescent migraineurs. These studies did not establish the efficacy of oral sumatriptan compared to placebo in the treatment of migraine in adolescents. Adverse events observed in these clinical trials were similar in nature to those reported in clinical trials in adults. The frequency of all adverse events in these patients appeared to be both dose- and age dependent, with younger patients reporting events more commonly than older adolescents.
  • Post-marketing experience documents that serious adverse events have occurred in the pediatric population after use of subcutaneous, oral, and/or intranasal sumatriptan. These reports include events similar in nature to those reported rarely in adults, including stroke, visual loss, and death. A myocardial infarction has been reported in a 14-year-old male following the use of oral sumatriptan; clinical signs occurred within 1 day of drug administration. Since clinical data to determine the frequency of serious adverse reactions in pediatric patients who might receive subcutaneous, oral, or intranasal sumatriptan are not presently available, the use of sumatriptan (transdermal) in patients under 18 years of age is not recommended.

Geriatic Use

  • Clinical trials of sumatriptan (transdermal) did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. Other reported clinical experience has not identified differences in responses between the elderly and younger subjects. In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function and of concomitant disease or other drug therapy.
  • A cardiovascular evaluation is recommended for geriatric patients who have other cardiovascular risk factors (e.g., diabetes, hypertension, smoking, obesity, strong family history of CAD) prior to using sumatriptan (transdermal)

Gender

There is no FDA guidance on the use of Sumatriptan (transdermal) with respect to specific gender populations.

Race

There is no FDA guidance on the use of Sumatriptan (transdermal) with respect to specific racial populations.

Renal Impairment

There is no FDA guidance on the use of Sumatriptan (transdermal) in patients with renal impairment.

Hepatic Impairment

There is no FDA guidance on the use of Sumatriptan (transdermal) in patients with hepatic impairment.

Females of Reproductive Potential and Males

There is no FDA guidance on the use of Sumatriptan (transdermal) in women of reproductive potentials and males.

Immunocompromised Patients

There is no FDA guidance one the use of Sumatriptan (transdermal) in patients who are immunocompromised.

Administration and Monitoring

Administration

  • Transdermal.

Monitoring

  • Monitoring of patients after overdose with sumatriptan (transdermal) should continue for at least 15 hours or while symptoms or signs persist.
  • Monitor blood pressure in patients treated with sumatriptan (transdermal).

IV Compatibility

There is limited information regarding the compatibility of Sumatriptan (transdermal) and IV administrations.

Overdosage

  • No gross overdoses in clinical practice have been reported. Coronary vasospasm was observed after intravenous administration of sumatriptan injection. Overdoses would be expected from animal data (dogs at 0.1 g/kg, rats at 2 g/kg) to possibly cause convulsions, tremor, inactivity, erythema of the extremities, reduced respiratory rate, cyanosis, ataxia, mydriasis, injection site reactions (desquamation, hair loss, and scab formation), and paralysis.
  • The apparent elimination half-life of sumatriptan after sumatriptan (transdermal) administration is about 3 hours, and therefore monitoring of patients after overdose with sumatriptan (transdermal) should continue for at least 15 hours or while symptoms or signs persist.
  • It is unknown what effect hemodialysis or peritoneal dialysis has on the serum concentrations of sumatriptan.

Pharmacology

Sumatriptan Structural Formula V.1.png
Sumatriptan-3D-balls.png
Sumatriptan (transdermal)
Systematic (IUPAC) name
1-[3-(2-Dimethylaminoethyl)-1H-indol-5-yl]-N-methyl-methanesulfonamide
Identifiers
CAS number 103628-46-2
ATC code N02CC01
PubChem 5358
DrugBank DB00669
Chemical data
Formula C14H21N3O2S 
Mol. mass 295.402 g/mol
SMILES eMolecules & PubChem
Pharmacokinetic data
Bioavailability 15% (oral)/ 96% (s.c)
Protein binding 14–21%
Metabolism MAO
Half life 2.5 hours
Excretion 60% urine; 40% feces
Therapeutic considerations
Licence data

US

Pregnancy cat.

C

Legal status

-only(US)

Routes tablet, subcutaneous injection, nasal spray

Mechanism of Action

  • Sumatriptan is the active component of sumatriptan (transdermal). Sumatriptan binds with high affinity to human cloned 5-HT1B/1D receptors. Sumatriptan presumably exerts its therapeutic effects in the treatment of migraine headache by binding to 5-HT1B/1D receptors located on intracranial blood vessels and sensory nerves of the trigeminal system.
  • Current theories proposed to explain the etiology of migraine headache suggest that symptoms are due to local cranial vasodilatation and/or to the release of sensory neuropeptides (including substance P and calcitonin gene-related peptide) through nerve endings in the trigeminal system. The therapeutic activity of sumatriptan for the treatment of migraine headaches is thought to be due to the agonist effects at the 5-HT1B/1D receptors on intracranial blood vessels (including the arterio-venous anastomoses) and sensory nerves of the trigeminal system, which result in cranial vessel constriction and inhibition of pro-inflammatory neuropeptide release.

Structure

  • Sumatriptan iontophoretic transdermal system is a disposable, single use system designed to deliver sumatriptan through the skin using iontophoresis. Iontophoresis is a non-invasive method of delivering a drug through the skin using a low electrical current. The sumatriptan (transdermal) electronics, powered by two coin cell lithium batteries, control the amount of current applied and the rate and amount of sumatriptan delivered.
  • Sumatriptan succinate, the active component of sumatriptan (transdermal), is a selective 5-hydroxy-tryptamine receptor subtype 1 (5-HT1) agonist (triptan). Sumatriptan succinate is chemically designated as 3-[2-(dimethylamino)ethyl]-N-methyl-indole-5-methanesulfonamide succinate (1:1), and has the following structure:
This image is provided by the National Library of Medicine.
  • The empirical formula is C14H21N3O2S•C4H6O4 representing a molecular weight of 413.5.
  • Sumatriptan succinate is a white to off-white powder that is freely soluble in water. Each sumatriptan (transdermal) iontophoretic transdermal system contains 86 mg sumatriptan (base) as the succinate salt in an aqueous formulation. Sumatriptan (transdermal), upon activation, delivers 6.5 mg of sumatriptan through the skin over 4 hours.
  • Sumatriptan (transdermal) iontophoretic transdermal system is composed of an iontophoretic device and a drug reservoir card. The reservoir card contains 2 non-woven pads and 2 different gel formulations; one a sumatriptan succinate formulation and the other a sodium salt formulation. The sumatriptan succinate formulation and pad contains the following inactive ingredients: purified water, basic butylated methacrylate copolymer (polyamine), lauric acid, adipic acid, methylparaben and a non-woven viscose pad. The salt formulation and pad contains: purified water, hydroxypropylcellulose, sodium chloride, methylparaben and a non-woven viscose pad. Sumatriptan (transdermal) is a non-sterile product.
  • The iontophoretic device consists of medical grade adhesive fabric and foam and a plastic dome that contains an activation button, batteries, and electronics (see Figure 2).

Figure 2: Iontophoretic Device

This image is provided by the National Library of Medicine.
  • The sumatriptan and salt pads are housed in individual reservoirs. Each reservoir is sealed by a foil strip that is removed prior to transfer of the pads to the iontophoretic device (see Figure 3). The iontophoretic device and foil reservoirs are co-packaged in a single unit pouch.

Figure 3: Reservoir Card

This image is provided by the National Library of Medicine.
  • For sumatriptan (transdermal) to function, the pads must completely cover the electrodes.

Pharmacodynamics

  • Blood Pressure: Significant elevation in blood pressure, including hypertensive crisis, has been reported in patients treated with sumatriptan, with and without a history of hypertension.
  • Peripheral (Small) Arteries: In healthy volunteers (N = 18), a trial evaluating the effects of sumatriptan on peripheral (small vessel) arterial reactivity failed to detect a clinically significant increase in peripheral resistance.
  • Heart Rate: Transient increases in blood pressure observed in some subjects in clinical trials carried out during sumatriptan’s development as a treatment for migraine were not accompanied by any clinically significant changes in heart rate.

Pharmacokinetics

  • Absorption and Bioavailability: Following sumatriptan (transdermal) administration to the upper arm the maximum mean sumatriptan serum concentration (Cmax) was 22 ng/mL, the mean total area under the curve (AUC0-inf) was 110 hr*ng/mL, and the median tmax was 1.1 hours. The mean Cmax and mean AUC0-inf measured after sumatriptan (transdermal) administration were approximately 37% and 45% of the values measured after administration of 100 mg Imitrex® tablets, respectively.
  • The effect of sumatriptan (transdermal) application to the upper arm versus thigh was assessed in 19 healthy subjects. The application sites are considered interchangeable as the relative bioavailability of sumatriptan following application of the sumatriptan (transdermal) TDS to these two sites was comparable.
  • Distribution: Protein binding, determined by equilibrium dialysis over the concentration range of 10 to 1000 ng/mL, is between 14% and 21%. The effect of sumatriptan on the protein binding of other drugs has not been evaluated. The apparent volume of distribution of sumatriptan is 2.4 L/kg.
  • Metabolism: In vitro studies with human microsomes suggest that sumatriptan is metabolized by MAO, predominantly the A isoenzyme. No new metabolites were identified in comparison with the oral sumatriptan tablets. Most of a radiolabeled sumatriptan dose that is excreted in the urine is the major metabolite indole acetic acid (IAA) or the IAA glucuronide, both of which are inactive.
  • Elimination: After a single sumatriptan (transdermal) dose in 9 subjects, 11% of the sumatriptan dose was excreted in the urine as unchanged sumatriptan and 69% as the indole acetic acid metabolite. After a single sumatriptan (transdermal) dose, the mean sumatriptan half-life was 3.1 hours.
  • Migraine Effect: Similar pharmacokinetic values were observed during a migraine attack compared to a migraine-free period following sumatriptan (transdermal) administration on the upper arm in 18 patients with a diagnosis of migraine.
  • External Heat Source: A heat effect study in 12 healthy adult subjects demonstrated similar pharmacokinetic values without and with the application of an external heat source (40ºC heat wrap placed over top of the sumatriptan (transdermal) TDS for the 4 hour dosing period).
  • Special Populations:
  • Age: The pharmacokinetics of sumatriptan after sumatriptan (transdermal) administration to the upper arm were compared for 8 healthy elderly subjects versus 8 paired gender and race matched healthy young adult subjects. No significant pharmacokinetic differences were observed.
  • Renal Impairment: The effect of renal impairment on the pharmacokinetics of sumatriptan has not been examined.
  • Hepatic Impairment: The effect of mild to moderate hepatic disease on the pharmacokinetics of subcutaneously administered sumatriptan has been evaluated. There were no significant differences in the pharmacokinetics of subcutaneously administered sumatriptan in moderately hepatically impaired subjects compared with healthy controls. The pharmacokinetics of subcutaneously administered sumatriptan in patients with severe hepatic impairment has not been studied. The use of sumatriptan (transdermal) in this population is contraindicated.
  • Race: The effect of race on sumatriptan pharmacokinetics after sumatriptan (transdermal) administration was assessed in an analysis of 8 pooled Phase 1 studies with 168 healthy subjects (50 non-Caucasian and 118 Caucasian). Cmax is about 8% lower and AUC0-4 hours is about 10% lower in non-Caucasian compared to Caucasian subjects, respectively. These differences are not expected to be clinically significant.
  • Gender: No effect of gender on sumatriptan pharmacokinetics was identified in a study in 17 healthy subjects (8 male and 9 female).
  • Drug Interaction Studies: Monoamine Oxidase-A Inhibitors: In a study of 14 healthy females, pretreatment with an MAO-A inhibitor decreased the clearance of sumatriptan, resulting in a 2-fold increase in the area under the sumatriptan plasma concentration-time curve (AUC), corresponding to a 40% increase in elimination half-life.

Nonclinical Toxicology

Carcinogenesis, Mutagenesis, Impairment of Fertility

  • Carcinogenesis: In carcinogenicity studies, rats and mice were given sumatriptan by oral gavage. Mice were dosed for 78 weeks and rats were dosed for 104 weeks. There was no evidence of an increase in tumors in either species related to sumatriptan administration.
  • Mutagenesis: Sumatriptan was not mutagenic in the presence or absence of metabolic activation when tested in two gene mutation assays (the Ames test and the in vitro mammalian Chinese hamster V79/HGPRT assay). It was not clastogenic in two cytogenetics assays (in vitro human lymphocyte assay and in vivo rat micronucleus assay).
  • Impairment of Fertility: A fertility study by the subcutaneous route, during which male and female rats were dosed daily with sumatriptan prior to and throughout the mating period, demonstrated no evidence of impaired fertility. However, following oral administration, a treatment-related decrease in fertility, secondary to a decrease in mating, was seen for rats treated with 50 and 500 mg/kg/day. It is not clear whether the problem is associated with the treatment of males or females or both.

Animal Toxicology and/or Pharmacology

  • Corneal Opacities: Dogs receiving oral sumatriptan developed corneal opacities and defects in the corneal epithelium. Corneal opacities were seen at the lowest dosage tested, 2 mg/kg/day, and were present after 1 month of treatment. Defects in the corneal epithelium were noted in a 60-week study. Earlier examinations for these toxicities were not conducted and no-effect doses were not established.
  • Melanin Binding: In rats with a single subcutaneous dose (0.5 mg/kg/day) of radiolabeled sumatriptan, the elimination half-life of radioactivity from the eye was 15 days, suggesting that sumatriptan and its metabolites bind to the melanin of the eye. The clinical significance of this binding is unknown.

Clinical Studies

Acute Migraine Attack – Placebo Controlled Efficacy Study

  • The efficacy of sumatriptan (transdermal) in the acute treatment of migraine headaches with or without aura was demonstrated in a randomized, double-blind, controlled study (Study 1).
  • Patients in Study 1 were predominantly female (85%) and Caucasian (82%), with a mean age of 41 years. Patients were instructed to treat a migraine headache of moderate to severe pain with a single sumatriptan (transdermal) TDS or matching TDS with no sumatriptan in the drug reservoir. Additional medications were allowed as rescue therapy beginning 2 hours after the initial treatment.
  • The primary efficacy endpoint in Study 1 was the proportion of patients who had no headache pain at 2 hours post TDS activation. Absence of nausea, photophobia, and phonophobia at 2 hours post TDS activation were assessed as secondary endpoints. Headache pain relief, defined as a reduction in migraine-related headache pain severity from moderate or severe pain to mild or no pain, was also assessed. As shown in Table 4, a significantly greater proportion of patients had no headache pain, had headache pain relief, no nausea, no phonophobia, or no photophobia at two hours after TDS activation in the sumatriptan (transdermal) treatment group than in the control group.
This image is provided by the National Library of Medicine.
  • Analyses of the relationship between age, race, gender, or BMI and response showed no significant differences in response rates.

How Supplied

  • Sumatriptan (transdermal) contains 86 mg sumatriptan that delivers 6.5 mg of sumatriptan over 4 hours.
  • After use, fold used system so the adhesive side sticks to itself and safely discard away from children and pets. Sumatriptan (transdermal) contains lithium-manganese dioxide batteries; dispose in accordance with state and local regulations.

Storage

  • Store at room temperature, between 20°C to 25°C (68°F to 77°F), with excursions permitted between 15°C to 30°C (59°F to 86°F). Do not store in the refrigerator or freezer.
  • Sumatriptan (transdermal) is packaged individually in a sealed pouch. Sumatriptan (transdermal) is supplied in cartons of 4 systems, NDC 51759-101-04.

Images

Drug Images

Package and Label Display Panel

This image is provided by the National Library of Medicine.
This image is provided by the National Library of Medicine.
This image is provided by the National Library of Medicine.
This image is provided by the National Library of Medicine.

Patient Counseling Information

  • How to Use ZECUITY
  • Advise patients to carefully read the Patient Instructions for Use. Only patients who are able to understand and follow the instructions should use ZECUITY.
  • Advise patients that the ZECUITY iontophoretic transdermal system (TDS) must be properly applied and activated within 15 minutes of initiating Step 1 (Pull Tabs) of the Patient Instructions for Use, or the TDS will not operate.
  • Advise patients not to bathe, shower or swim while wearing ZECUITY.
  • Advise patients that upon removal of the ZECUITY TDS, most patients experience some skin redness under the transdermal system, which usually disappears within 24 hours.
  • Advise patients that Zecuity is single-use and should not be cut. Advise patients that no more than two ZECUITY TDS should be used in a 24 hour period, and that a second ZECUITY TDS should not be applied until at least 2 hours after activation of the first ZECUITY TDS.
  • Instruct patients to apply the ZECUITY TDS to the upper arm or thigh and not to other areas of the body. Instruct patients to apply the ZECUITY TDS to dry intact, non-irritated skin on a site that is relatively hair free and without scars, tattoos, abrasions, or other skin conditions (i.e., generalized skin irritation or disease including eczema, psoriasis, melanoma, contact dermatitis).
  • Advise patients that the ZECUITY TDS should not be applied to a previous application site until the site remains erythema free for 3 days.
  • Inform patients that the safety of using more than 4 ZECUITY in one month has not been established.
  • Risk of Injury during Magnetic Resonance Imaging (MRI) procedure
  • Inform patients that Zecuity contains metal parts and must be removed before an MRI procedure.
  • Potential for Allergic Contact Dermatitis
  • Caution patients about the potential for developing allergic contact dermatitis (ACD) after use of ZECUITY. Inform patients of the signs and symptoms of ACD, and instruct patients to seek medical advice if they develop skin lesions suggestive of ACD. Inform patients that it is possible that some patients who develop ACD with sumatriptan by exposure to ZECUITY may not be able to take sumatriptan in any form.
  • Risk of Myocardial Ischemia and/or Infarction, Prinzmetal’s Angina, Other Vasospasm-related Events, Arrhythmias, and Cerebrovascular Events
  • Inform patients that the medication in ZECUITY or other triptans may cause serious cardiovascular side effects such as myocardial infarction or stroke, which may result in hospitalization and even death. Although serious cardiovascular events can occur without warning symptoms, advise patients that they should be alert for the signs and symptoms of chest pain, shortness of breath, weakness, slurring of speech, and should seek medical advice when observing any indicative sign or symptoms. Apprise patients of the importance of this follow-up.
  • Anaphylactic/Anaphylactoid Reactions
  • Inform patients that anaphylactic/anaphylactoid reactions have occurred in patients receiving sumatriptan. Such reactions can be life threatening or fatal. In general, anaphylactic reactions to drugs are more likely to occur in individuals with a history of sensitivity to multiple allergens.
  • Medication Overuse Headache
  • Inform patients that use of acute migraine drugs for 10 or more days per month may lead to an exacerbation of headache and encourage patients to record headache frequency and drug use (e.g., by keeping a headache diary).
  • Pregnancy
  • Inform patients that ZECUITY should not be used during pregnancy unless the potential benefit justifies the potential risk to the fetus.
  • Nursing Mothers
  • Advise patients to notify their physician if they are breast-feeding or plan to breast-feed.
  • Ability To Perform Complex Tasks
  • Since migraines or treatment with sumatriptan may cause somnolence and dizziness, instruct patients to evaluate their ability to perform complex tasks during migraine attacks and after using ZECUITY.
  • Serotonin Syndrome
  • Caution patients about the risk of serotonin syndrome with the use of ZECUITY or other triptans, particularly during combined use with SSRIs, SNRIs, TCAs, and MAO inhibitors.

Patient Package Insert

This image is provided by the National Library of Medicine.

Instructions For Use

This image is provided by the National Library of Medicine.

Precautions with Alcohol

Alcohol-Sumatriptan (transdermal) interaction has not been established. Talk to your doctor about the effects of taking alcohol with this medication.

Brand Names

Look-Alike Drug Names

  • SUMAtriptan - sitaGLIPtin[2]
  • SUMAtriptan - ZOLMitriptan[2]

Drug Shortage Status

Price

References

The contents of this FDA label are provided by the National Library of Medicine.

  1. "ZECUITY- sumatriptan succinate patch, extended release, electrically controlled".
  2. 2.0 2.1 "https://www.ismp.org". External link in |title= (help)

Linked-in.jpg